close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Belite Bio, Inc - American Depositary Shares (NQ:BLTE)

158.50 +2.56 (+1.64%)
Delayed Quote Updated: 10:22 AM EST, Nov 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Belite Bio, Inc - American Depositary Shares

< Previous 1 2 3 4 Next >
News headline image
Belite Bio Wins FDA Priority Review for Tinlarebant in Stargardt Disease ↗
Belite Bio (NASDAQ:BLTE) said the U.S. Food and Drug Administration has accepted its new drug application for tinlarebant as a treatment for Stargardt disease type 1, granted the application priority... 
Via MarketBeat
News headline image
Belite Bio Q2 Earnings Call Highlights ↗
Belite Bio (NASDAQ:BLTE) said the U.S. Food and Drug Administration has accepted its New Drug Application for tinlarebant, an investigational treatment for Stargardt disease, and granted the... 
Via MarketBeat
Topics Earnings
News headline image
Full Transcript: Belite Bio Q2 2026 Earnings Call ↗
Belite Bio (NASDAQ:BLTE) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This content is powered by... 
Via Benzinga
Topics Earnings
News headline image
Belite Bio Conference Highlights Tinlarebant Data and New Hope for Retinal Diseases ↗
Panelists at the H.C. Wainwright Sixth Annual Ophthalmology Virtual Conference said investigational therapies for inherited retinal disorders could begin to reshape treatment options for Stargardt... 
Via MarketBeat
Belite Bio Inc - ADR (NASDAQ:BLTE) Reports Narrower-Than-Expected Q4 Loss, NDA Submission on Track for 2026 ↗
Via Chartmill
News headline image
Earnings Scheduled For November 10, 2025 ↗
 
Via Benzinga
News headline image
Earnings Outlook For Belite Bio ↗
 
Via Benzinga
News headline image
Belite Bio Eyes Priority FDA Review as Tinlarebant Targets Stargardt Disease ↗
Belite Bio (NASDAQ:BLTE) Chief Medical Officer Hendrik Scholl said the company is advancing its lead compound, Tinlarebant, as a potential treatment for Stargardt disease and geographic atrophy... 
Via MarketBeat
News headline image
Belite Bio Q1 Earnings Call Highlights ↗
Belite Bio (NASDAQ:BLTE) said it has begun a rolling New Drug Application submission to the U.S. Food and Drug Administration for Tinlarebant in Stargardt disease, while also accelerating preparations... 
Via MarketBeat
Topics Earnings
News headline image
Belite Bio (BLTE) Q1 2026 Earnings Transcript ↗
Belite Bio (BLTE) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Belite Bio's Earnings Outlook ↗
 
Via Benzinga
News headline image
Earnings Outlook For Belite Bio ↗
 
Via Benzinga
News headline image
Earnings Scheduled For November 12, 2024 ↗
 
Via Benzinga
News headline image
Insights into Belite Bio's Upcoming Earnings ↗
 
Via Benzinga
News headline image
Belite Bio (BLTE) Q4 2025 Earnings Call Transcript ↗
Belite Bio (BLTE) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Why Belite Bio Stock Soared on Monday ↗
The company is now tantalizingly close to commercializing its leading drug candidate. 
Via The Motley Fool
News headline image
Top movers in Monday's pre-market session ↗
Before the US market kicks off on Monday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
News headline image
Expert Ratings for Belite Bio ↗
 
Via Benzinga
News headline image
Expert Ratings for Belite Bio ↗
 
Via Benzinga
News headline image
The Latest Analyst Ratings for Belite Bio ↗
 
Via Benzinga
News headline image
3 Lesser-Known Healthcare Names With Major Upside in Store ↗
These are three healthcare stocks offering a compelling combination of secure business, strong fundamentals, and growth opportunity. 
Via MarketBeat
News headline image
Dycom Industries Posts Upbeat Earnings, Joins WeRide, Keysight Technologies And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
Belite Bio Analysts See Potential For Stock Gains With Progress In Key Trials ↗
Belite Bio Inc (NASDAQ: BLTE) stock falls after reporting Q3 net loss of $36.1M; analysts maintain Buy/Overweight rating, citing positive trial results. 
Via Benzinga
News headline image
Earnings Scheduled For March 17, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For August 11, 2025 ↗
 
Via Benzinga
News headline image
BLTE Stock Earnings: Belite Bio Misses EPS for Q2 2024 ↗
BLTE stock results show that Belite Bio missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
BLTE Stock Earnings: Belite Bio Misses EPS for Q1 2024 ↗
BLTE stock results show that Belite Bio missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
Why 22nd Century Group Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
Gainers Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) shares jumped 283.7% to $1.3007 after Harmony Biosciences entered into definitive agreement to acquire the company for total potential consideration... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For July 28, 2023 ↗
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For July 26, 2023 ↗
 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.